Thyroid Hormone T4 (Thyroxine) Suppression: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Thyroid Hormone T4 Suppression Therapy |FDA_approval=No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved) |used_for=Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status |clinical_trial_phase=Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041) |common_side_effects=Carefully monitore...") |
No edit summary |
||
| Line 11: | Line 11: | ||
|category=Nutraceuticals and Herbals | |category=Nutraceuticals and Herbals | ||
|links=NCT02654041 | |links=NCT02654041 | ||
|toxicity_level=2 | |||
|toxicity_explanation=The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider. | |||
}} | }} | ||
Revision as of 08:55, 27 March 2024
| Property | Information |
|---|---|
| Drug Name | Thyroid Hormone T4 Suppression Therapy |
| FDA Approval | No (Used off-label for cancer treatment; specific regimen for cancer not FDA-approved) |
| Used for | Investigational use in cancer treatment, particularly in glioblastoma, based on observations of improved outcomes with hypothyroid status |
| Clinical Trial Phase | Early clinical trials and case studies, including a phase 2 clinical trial in Israel (NCT02654041) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Carefully monitored to avoid clinical symptoms of hypothyroidism; includes potential for fatigue if not properly managed |
| OS without | Not specified |
| OS with | In early studies, hypothyroid patients showed median survival of 10.1 months compared to 3.1 months in non-hypothyroid patients. Remarkable long-term survivors in informal cohort studies with advanced cancer, including glioblastoma patients surviving 36 and 48 months.Property "Has OS with" (as page type) with input value "In early studies, hypothyroid patients showed median survival of 10.1 months compared to 3.1 months in non-hypothyroid patients. Remarkable long-term survivors in informal cohort studies with advanced cancer, including glioblastoma patients surviving 36 and 48 months." contains invalid characters or is incomplete and therefore can cause unexpected results during a query or annotation process. |
| PFS without | Not specified |
| PFS with | Not specifically documented; focus on overall survival improvements |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The toxicity level of Thyroid Hormone T4 Suppression Therapy is rated as a 2, which indicates a low level of toxicity. This is because the therapy is designed to suppress the hormone levels in the body and replace them with a synthetic version to help fight cancer cells. The side effects, such as fatigue, are typically manageable, especially when the treatment is carefully monitored. Nonetheless, this therapy is not without potential side effects and it is applied off-label, hence it's necessary to discuss with your healthcare provider. |
Notes: Thyroid Hormone T4 Suppression Therapy involves inducing chemical hypothyroidism via propylthiouracil or suppressing T4 levels with methimazole and supplementing with synthetic T3 (Cytomel) to mitigate cancer-promoting effects of thyroid hormones while avoiding hypothyroidism symptoms. Discovery of thyroid hormone receptors on cancer cells provides a mechanism for their potential cancer-promoting effects. Early studies and case reports suggest potential benefits in cancer treatment, especially glioblastoma, with notable long-term survival in some patients. Further research, including ongoing clinical trials, is needed to validate these findings and optimize treatment protocols.
Links: NCT02654041
From Ben Williams Book: Not specified
Loading comments...
